An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024. Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed better results ⁠in patients with the skin disease and obesity in a late-stage study, compared to Taltz alone.